Group of rare blood cancers respond to new treatment pioneered by Stanford physician
A global trial of an oral medication called midostaurin indicates that the drug can produce partial or complete resolution of organ damage in 60 percent of patients with a group of rare blood cancers known collectively as ...
Jun 29, 2016
0
52